Qualigen Therapeutics, Inc. (QLGN) Tops Q2 EPS by 5c

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) reported Q2 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.31 million.

For earnings history and earnings-related data on Qualigen Therapeutics, Inc. (QLGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c